AstraZeneca PLC (NASDAQ:AZN – Free Report) – Equities researchers at Zacks Research lifted their Q3 2025 earnings estimates for AstraZeneca in a research report issued to clients and investors on Wednesday, August 28th. Zacks Research analyst R. Department now forecasts that the company will earn $1.17 per share for the quarter, up from their previous forecast of $1.15. The consensus estimate for AstraZeneca’s current full-year earnings is $4.06 per share.
AstraZeneca (NASDAQ:AZN – Get Free Report) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.01. The business had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the business earned $1.08 EPS.
Check Out Our Latest Stock Report on AZN
AstraZeneca Stock Performance
AZN stock opened at $87.62 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm has a market cap of $271.67 billion, a PE ratio of 42.95, a P/E/G ratio of 1.63 and a beta of 0.45. The business has a 50 day moving average of $80.81 and a 200-day moving average of $74.91. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68.
AstraZeneca Cuts Dividend
The company also recently declared a Semi-Annual dividend, which will be paid on Monday, September 9th. Shareholders of record on Friday, August 9th will be given a dividend of $0.49 per share. The ex-dividend date is Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s payout ratio is 48.04%.
Hedge Funds Weigh In On AstraZeneca
Large investors have recently modified their holdings of the company. Strategic Investment Solutions Inc. IL purchased a new position in AstraZeneca in the 2nd quarter worth $362,000. Clearbridge Investments LLC grew its stake in shares of AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after buying an additional 186,010 shares during the last quarter. Dana Investment Advisors Inc. purchased a new position in shares of AstraZeneca in the second quarter worth about $204,000. Granite Bay Wealth Management LLC bought a new stake in shares of AstraZeneca in the 2nd quarter valued at about $332,000. Finally, Truist Financial Corp boosted its holdings in AstraZeneca by 4.6% during the 2nd quarter. Truist Financial Corp now owns 250,478 shares of the company’s stock valued at $19,535,000 after acquiring an additional 11,074 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
- Five stocks we like better than AstraZeneca
- What Are Dividend Contenders? Investing in Dividend Contenders
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 8/26 – 8/30
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.